logo
FDA approves lab-grown salmon

FDA approves lab-grown salmon

Yahoo5 hours ago

The FDA has greenlit the first lab-grown fish for public consumption, and it's already available in a restaurant. The dish's developers at the startup Wildtype confirmed the regulatory milestone last week, but for now, hungry and curious taste-testers will need to head to Portland, Oregon, to sample the company's 'cultivated salmon.'
'We're proud to share that we completed a thorough pre-market safety consultation with [the] FDA,' Wildtype said in its announcement along with a link to the agency's response letter.
FDA's Director Office of Food Chemical Safety, Dietary Supplements, and Innovation Human Foods Program confirmed the agency has 'no questions at this time' about Wildtype's 'cultured salmon cell material,' and described it 'as safe as comparable foods produced by other methods.'
As The Verge notes, such consultations are entirely voluntary for companies, but can still serve as a means to boost consumer confidence and help legitimize a product.
Wildtype's salmon is not the first lab-grown food to receive the FDA's stamp of approval—that honor went to two companies' cultured chicken in 2022—but this does mark the first time a lab-grown fish has earned the distinction. What makes Wildtype's project particularly distinctive is its choice of salmon cut. Unlike lab-grown chicken or beef, the company is creating sushi-grade 'saku' cuts that are intended to be eaten raw. These uniformly cut blocks of fish are most often served as sashimi, and do not require any cook time.
To achieve this, Wildtype's researchers first harvest living cells from Pacific salmon before transporting them for cultivation. In specially designed equipment, these cells are then grown in cultures with conditions similar to those in the wild fish itself. These include fine-tuned pH levels, temperatures, nutrients, and other factors that induce the cells to develop to a point when engineers can harvest them. From there, the team integrates 'a few plant-based ingredients' to help hone the flavor, texture, and appearance of wild salmon filets.
Wildtype's cultivated salmon debuted in late May at Kann, a James Beard Award-winning Haitian restaurant located in Portland, Oregon. Overseen by chef Gregoary Goudet, the saku cuts are currently paired with spiced tomato, pickled strawberry, strawberry juice, and a rice cracker topped with epis, a pesto-like traditional Haitian blend of garlic, peppers, and herbs. Kann will begin including the salmon on its daily menu in July, while Wildtype says another four restaurants plan to integrate the fish into their own dishes in the coming months.
The next restaurants have yet to be named, but they likely won't be located in one of the eight states that have already instituted bans on serving lab-grown meat. These prohibitions aren't based on any particularly well-founded concerns, however. Critics frequently cite a threat to the farming industry, but given the comparative costs, lab-grown meat isn't likely to supplant traditional options anytime soon.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Yahoo

time23 minutes ago

  • Yahoo

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

- Composition of matter patent affirmed, provides protection into 2030 - Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038 SAN DIEGO, June 09, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent established in Allergan USA, Inc. v. MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, holding that "a first filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date." "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for NUPLAZID, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for NUPLAZID 34 mg capsule formulation into 2038," said Catherine Owen Adams, Chief Executive Officer. "These decisions reinforce our commitment to safeguarding the intellectual property that underpins our innovations in addressing serious, unmet medical needs." This follows the U.S. District Court for the District of Delaware ruling in favor of Acadia regarding its '721 formulation patent for NUPLAZID which ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," "continue" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the impact of the court ruling on our business and our ability to defend ourselves in the future; (ii) the continued patent protection for NUPLAZID; and (iii) the anticipated timing for termination of such protections. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our ability to maintain, protect and enhance our intellectual property; the outcome of other existing and potential future lawsuits challenging our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-Q for the quarter ended March 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law. View source version on Contacts Investor Contacts: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID ® (pimavanserin) Composition of Matter Patent
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID ® (pimavanserin) Composition of Matter Patent

Business Wire

timean hour ago

  • Business Wire

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID ® (pimavanserin) Composition of Matter Patent

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID ® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent established in Allergan USA, Inc. v. MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, holding that 'a first filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date.' 'We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for NUPLAZID, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for NUPLAZID 34 mg capsule formulation into 2038,' said Catherine Owen Adams, Chief Executive Officer. 'These decisions reinforce our commitment to safeguarding the intellectual property that underpins our innovations in addressing serious, unmet medical needs.' This follows the U.S. District Court for the District of Delaware ruling in favor of Acadia regarding its '721 formulation patent for NUPLAZID which ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' 'continue' and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the impact of the court ruling on our business and our ability to defend ourselves in the future; (ii) the continued patent protection for NUPLAZID; and (iii) the anticipated timing for termination of such protections. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our ability to maintain, protect and enhance our intellectual property; the outcome of other existing and potential future lawsuits challenging our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-Q for the quarter ended March 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.

Zacks Industry Outlook Penumbra, Integer and AngioDynamics
Zacks Industry Outlook Penumbra, Integer and AngioDynamics

Yahoo

timean hour ago

  • Yahoo

Zacks Industry Outlook Penumbra, Integer and AngioDynamics

Chicago, IL – June 9, 2025 – Today, Zacks Equity Research discusses Penumbra PEN, Integer Holdings ITGR and AngioDynamics ANGO. Link: Over the past year, advancements in artificial intelligence (AI) and predictive analytics have rapidly revolutionized the Medical Instruments industry, driving innovation in diagnostics, patient monitoring and personalized treatment. AI-powered devices now process large datasets in real time, delivering accurate predictions and actionable insights. Predictive analytics supports early disease detection, risk assessment, maintenance optimization, and cost reduction. According to a January 2025 report, genAI is already generating synthetic medical images, simulating disease progression, and accelerating drug discovery. However, it also introduces new regulatory challenges around safety, transparency, and data integrity. In response, the FDA is implementing a Total Product Lifecycle (TPLC) oversight model with a risk-based approach and enhanced post-market monitoring. Going by data, global AI in the healthcare market is projected to witness a CAGR of 38.5% from 2024 to 2030. However, a deteriorating geopolitical situation, tariffs and supply chain bottlenecks, resulting in a tough situation related to raw material and labor costs, freight charges, as well as healthcare staffing shortages, have put the industry in a tight spot again. Meanwhile, industry players like Penumbra, Integer Holdings and AngioDynamics have adapted well to changing consumer preferences and have been witnessing an uptrend in their stock prices. The Zacks Medical - Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. This FDA-regulated sector encompasses a vast array of products, from transcatheter valves and orthopedic devices to advanced imaging equipment and robotics. Recent trends highlight the integration of AI in diagnostics, the expansion of telemedicine, the rise of robotic-assisted surgeries, and developments in 3D printing, continuous glucose monitoring systems, gene editing, and nanomedicine. The emergence of generative AI is also reshaping MedTech, prompting the FDA to adopt a TPLC regulatory approach. Over the past couple of years, there has been a significant increase in the adoption of genAI within the medical instruments space, with "hyper-personalization" being the primary feature of genAI-driven treatment options. Added to this, genAI is rapidly paving the way for efficient operational management within the industry. GenAI, while analyzing vast and complex genetic and molecular data, is expected to help healthcare reach new heights in terms of predictive treatment options and smart hospital systems. A December 2024 report says that global genAI in the healthcare market was valued at $1.8 billion in 2023 and is expected to witness a CAGR of 33.2% from 2024 to 2032. Rapid advancement in deep learning and natural language processing, increasing demand for personalized treatment, growing investment in healthcare AI and rising healthcare data volumes are the major growth factors. This apart, the application of AI in the diagnostics space is growing enormously with the market expected to witness a CAGR of 24.6% by 2034. : The medical instruments space has been benefiting from the ongoing merger and acquisition (M&A) trend. It is a known fact that smaller and mid-sized industry players attempt to compete with the big shots through consolidation. The big players attempt to enter new markets through a niche product. Going by a J.P. Morgan report of 2025, in 2024, MedTech acquisition activity exceeded the previous two years in both deal count and total announced value. A total of 305 M&A transactions were announced, totaling over $63.1 billion for companies in medical devices, diagnostics, therapeutic digital health and commercial research tools, up from 134 deals in 2023. In 2025 so far, notable examples of M&A include Stryker's $4.9 billion acquisition of Inari Medical to expand its peripheral thrombectomy portfolio, Thermo Fisher's $4.1 billion purchase of Solventum's Purification & Filtration business, and Boston Scientific's $664 million acquisition of Bolt Medical to strengthen its position in intravascular lithotripsy solutions. : Per IMF's April 2025 World Economic Outlook, global growth is expected to remain lackluster over the next couple of years. At 2.8% in 2025 and 3.0% in 2026, the forecasts for growth are below the historical (2000–19) average of 3.7%. A few countries, especially low-income developing countries, have seen sizable downside growth revisions, often as a result of increased conflicts and recent tariff shocks. The good news is that global headline inflation is expected to decline to 4.3% in 2025 and to 3.6% in 2026, with advanced economies reaching the targets sooner than emerging market and developing economies. However, the IMF apprehends that the current policy-generated disruptions to the ongoing disinflation process could interrupt the pivot to easing monetary policy, with implications for fiscal sustainability and financial stability. Further, there are chances of higher nominal wage growth, which in some cases reflects the catch-up of real wages, accompanied by weak productivity, which could make it difficult for firms to moderate price increases, especially when profit margins are already squeezed. The Zacks Medical Instruments industry's Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates gloomy near-term prospects. The industry, housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #131, which places it in the bottom 46% of 244 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. We will present a few stocks that have the potential to outperform the market based on a strong earnings outlook. But it's worth taking a look at the industry's shareholder returns and current valuation first. The industry has underperformed the Zacks S&P 500 composite but outperformed the sector in the past year. The industry has declined 12.7% compared with the broader sector's decline of 14.7%. The S&P 500 has surged 12.8% in a year. On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 29.04X compared with the broader industry's 19.18X and the S&P 500's 21.83X. Over the past five years, the industry has traded as high as 40.60X, as low as 25.62X and at the median of 32.52X. Integer Holdings: Plano, TX-based Integer Holdings is a medical device contract development and manufacturing organization. Its strategic focus on portfolio optimization, including the divestiture of its Non-Medical business, supports its long-term inorganic growth plans. Integer Holdings has established a solid position in the MedTech industry and continues to invest in research and product development, which bodes well for innovation and future revenue growth. The Zacks Consensus Estimate for this Zacks Rank #1 (Strong Buy) company's 2025 sales is pegged at $1.87 billion, indicating a 7.7% rise from 2024. The consensus mark for Integer Holdings' 2025 EPS is pegged at $6.33, indicating an increase of 19.4% from 2024. AngioDynamics: Headquartered in Latham, NY, AngioDynamics' solid prospects with NanoKnife and an increased focus on cancer treatment markets are encouraging. The company boasts a robust product pipeline and strong momentum in geographic expansion. Continued strong sales of Auryon, AlphaVac, and NanoKnife products further strengthen AngioDynamics' outlook. The consensus estimate for this Zacks Rank #1 company's fiscal 2026 sales is pegged at $305 million, indicating a 6.3% rise from fiscal 2025. The consensus mark for AngioDynamics' fiscal 2026 EPS is pegged at a loss of 24 cents, indicating an improvement of 14.9% from the year-ago period figure. Penumbra: Alameda, CA-based Penumbra's consistent revenue growth momentum is being driven by strong patient outcomes with Lightning Flash 2.0, Lightning Bolt 7 and RED 72. The company's vascular and neuro businesses are showing encouraging growth trends. Penumbra's Immersive Healthcare business too is making progress. The Zacks Consensus Estimate for Penumbra's 2025 sales is pegged at $1.35 billion, indicating a 13.4% rise from 2024. The consensus mark for Penumbra's 2025 EPS is pegged at $3.72, indicating an improvement of 67.6% from the year-ago period figure. Penumbra has a Zacks Rank #2 (Buy) currently. You can see the complete list of today's Zacks #1 Rank stocks here. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store